Findings on Factor Xa Reported by Investigators at Zhejiang University (Prothrombin Complex Concentrates and Andexanet for Management of Direct Factor Xa Inhibitor Related Bleeding: a Meta-analysis)

摘要

2021 MAY 07 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Current study results on Proteins - Factor Xa have been published. According to news originating from Zhejiang, People's Republic of China, by NewsRx correspondents, research stated, "There are potential concerns related to bleeding caused by oral anticoagulants, especially in the elderly. Andexanet alfa has been authorized for use to reverse the effects of oral anticoagulants." Financial support for this research came from Jinhua City Science and Technology Plan Project Social Development Key Project. Our news journalists obtained a quote from the research from Zhejiang University, "Off-label use of four factor prothrombin complex concentrate (4F-PCC) for the reversal of oral factor Xa inhibitors is common. However, not much is known about their efficacy and safety profile.